| Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein. | |
| | |
MedLine Citation:
|
PMID: 23288701 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Oncogenic rearrangements of the TFE3 transcription factor gene are found in two distinct human cancers. These include ASPSCR1-TFE3 in all cases of alveolar soft part sarcoma (ASPS) and ASPSCR1-TFE3, PRCC-TFE3, SFPQ-TFE3, and others in a subset of pediatric and adult RCCs. Here, we examined the functional properties of the ASPSCR1-TFE3 fusion oncoprotein, defined its target promoters on a genome-wide basis, and performed a high throughput RNA interference screen to identify which of its transcriptional targets contribute to cancer cell proliferation. We first confirmed that ASPSCR1-TFE3 has a predominantly nuclear localization and functions as a stronger transactivator than native TFE3. Genome-wide location analysis performed on the FU-UR-1 cell line which expresses endogenous ASPSCR1-TFE3 identified 2193 genes bound by ASPSCR1-TFE3. Integration of these data with expression profiles of ASPS tumor samples and inducible cell lines expressing ASPSCR1-TFE3 defined a subset of 332 genes as putative upregulated direct targets of ASPSCR1-TFE3, including MET (a previously known target gene), and 64 genes as down-regulated targets of ASPSCR1-TFE3. As validation of this approach to identify genuine ASPSCR1-TFE3 target genes, two up-regulated genes bound by ASPSCR1-TFE3, CYP17A1 and UPP1, were shown by multiple lines of evidence to be direct, endogenous targets of transactivation by ASPSCR1-TFE3. As the results indicated that ASPSCR1-TFE3 functions predominantly as a strong transcriptional activator, we hypothesized that a subset of its upregulated direct targets mediate its oncogenic properties. We therefore chose 130 of these upregulated direct target genes to study in high-throughput RNAi screens using FU-UR-1 cells. In addition to MET, we provide evidence that 11 other ASPSCR1-TFE3 target genes contribute to the growth of ASPSCR1-TFE3-positive cells. Our data suggest new therapeutic possibilities for cancers driven by TFE3 fusions. More generally, this work establishes a combined integrated genomics / functional genomics strategy to dissect the biology of oncogenic, chimeric transcription factors. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
| | |
Authors:
|
Rachel Kobos; Makoto Nagai; Masumi Tsuda; Man Yee Merl; Tsuyoshi Saito; Marick Laé; Qianxing Mo; Adam Olshen; Steven Lianoglou; Christina Leslie; Irina Ostrovnaya; Christophe Antczak; Hakim Djaballah; Marc Ladanyi |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-3 |
Journal Detail:
|
Title: The Journal of pathology Volume: - ISSN: 1096-9896 ISO Abbreviation: J. Pathol. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-4 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0204634 Medline TA: J Pathol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
Affiliation:
|
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Calculation of wave-functions with frozen orbitals in mixed quantum mechanics/molecular mechanics me...
Next Document: Gemfibrozil Pretreatment Resulted in a Sexually Dimorphic Outcome in the Rat Models of Global Cerebr...